{
  "drug_name": "Warfarin",
  "url": "https://wikem.org/wiki/Warfarin",
  "scraped_at": "2026-01-10T02:46:24.383681",
  "sections": {
    "General": "Type:\nanticoagulant\nDosage Forms: oral\nCommon Trade Names: Coumadin",
    "Adult_Dosing": "Day 1: 5 - 7.5mg oral at bedtime (to ensure absorption on empty stomach)\nDay 2 and beyond: 2.5 - 7.5mg daily (usually 5mg)\nINR increase of >0.3 - 0.4 per day requires dose reduction\nResponse also influenced by congestive heart failure, liver disease, Vitamin K deficiency, many drugs\nTarget Range of INR\n2.5 - 3.5: Mechanical prosthetic valves or recurrent thromboembolism\n2.0 - 3.0: All other indications",
    "Pediatric_Dosing": "Safety and efficacy not well-established, though it is sometimes used in pediatrics for VTE treatment",
    "Special_Populations": "Pregnancy Rating\n: Contraindicated (Category D)\nLactation risk\n: infant risk minimal\nRenal Dosing: caution advised\nHepatic Dosing: consider decreased dose",
    "Contraindications": "Allergy to class/drug\nActive bleeding or tendency to bleed",
    "Adverse_Reactions": "Bleeding\nRisk increased when INR >3\nExponential increase when INR >5\nAvoid giving NSAIDs, sulfas, macrolidies (azithromycin ok), fluoroquinolones\nSkin necrosis\nUsually in patient with protein C deficiency\nOccurs 3 - 8 days after starting treatment\nTreatment: see\nWarfarin (Coumadin) Reversal",
    "Pharmacology": "Half-life: 20-60h (anticoagulant effect)\nOf note, half-life highly variable based on rate of clotting factor catabolism\nMetabolism: Liver\nExcretion: Urine 92%, bile\nMechanism of Action:\nBlocks activation of vitamin K dependent prothrombotic factors II, VII, IX, X\nBlocks synthesis of vitamin K dependent antithrombotic proteins C and S\nAlbumin bound",
    "Comments": "Because of differing factor half-lives, can cause transient (24-36 hour) prothrombosis at start of therapy\nBridge with\nheparin\nfor 1-2 days until INR is in desired range"
  }
}